Bicycle Therapeutics plc (BCYC) — Analyst outlook / Analyst consensus target is. Based on 21 analyst ratings, the consensus is bullish — 17 Buy, 4 Hold.
The consensus price target is $11.00 (low: $8.00, high: $13.00), representing an upside of 117.4% from the current price $5.06.
Analysts estimate Earnings Per Share (EPS) of $-3.02 and revenue of $0.04B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.29 vs est $-3.02 (beat +90.4%). 2025: actual $-3.16 vs est $-3.86 (beat +18%). Analyst accuracy: 0%.
BCYC Stock — 12-Month Price Forecast
$11.00
▲ +117.39% Upside
Average Price Target
Based on 21 Wall Street analysts offering 12-month price targets for Bicycle Therapeutics plc, the average price target is $11.00, with a high forecast of $13.00, and a low forecast of $8.00.
The average price target represents a +117.39% change from the last price of $5.06.
Highest Price Target
$13.00
Average Price Target
$11.00
Lowest Price Target
$8.00
BCYC Analyst Ratings
Buy
Based on 21 analysts giving stock ratings to Bicycle Therapeutics plc in the past 3 months
EPS Estimates — BCYC
0%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$0.29
vs Est –$3.02
▲ 940.8% off
2025
Actual –$3.16
vs Est –$3.86
▲ 22.0% off
Profitability Outlook
Company has been making losses in all recent fiscal years. Analysts expect losses to continue near-term.
Revenue Estimates — BCYC
69%
Analyst Accuracy
Fair
2 years compared
Actual vs Estimate
2024
Actual $0.035B
vs Est $0.037B
▼ 5.7% off
2025
Actual $0.073B
vs Est $0.032B
▲ 55.4% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
